JP2021510710A5 - - Google Patents
Info
- Publication number
- JP2021510710A5 JP2021510710A5 JP2020539000A JP2020539000A JP2021510710A5 JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5 JP 2020539000 A JP2020539000 A JP 2020539000A JP 2020539000 A JP2020539000 A JP 2020539000A JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- cdr2
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/072607 | 2018-01-15 | ||
| CN2018072607 | 2018-01-15 | ||
| PCT/CN2019/071711 WO2019137548A1 (en) | 2018-01-15 | 2019-01-15 | Antibodies and variants thereof against tigit |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021510710A JP2021510710A (ja) | 2021-04-30 |
| JPWO2019137548A5 JPWO2019137548A5 (https=) | 2022-02-07 |
| JP2021510710A5 true JP2021510710A5 (https=) | 2022-02-07 |
| JP7316284B2 JP7316284B2 (ja) | 2023-07-27 |
Family
ID=67219401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539000A Active JP7316284B2 (ja) | 2018-01-15 | 2019-01-15 | Ｔｉｇｉｔに対する抗体及びその多様体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11708410B2 (https=) |
| EP (1) | EP3740508A4 (https=) |
| JP (1) | JP7316284B2 (https=) |
| KR (1) | KR20200109313A (https=) |
| CN (1) | CN111601826B (https=) |
| AU (1) | AU2019207296A1 (https=) |
| CA (1) | CA3088332A1 (https=) |
| IL (1) | IL275737A (https=) |
| SG (1) | SG11202005595YA (https=) |
| TW (1) | TW201932489A (https=) |
| WO (1) | WO2019137548A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| EP4238991A4 (en) * | 2020-11-23 | 2024-05-15 | Guangdong Fapon Biopharma Inc. | ANTI-TIGIT ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN115466327B (zh) * | 2021-06-10 | 2025-07-08 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| AU2022330896A1 (en) * | 2021-08-20 | 2024-02-22 | Akeso Biopharma, Inc. | FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-βR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| CN118591557A (zh) * | 2022-01-24 | 2024-09-03 | 原启生物科技(上海)有限责任公司 | 靶向tigit的抗原结合蛋白及其用途 |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024041639A1 (en) * | 2022-08-26 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting tigit and uses thereof |
| CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| WO2025002151A1 (zh) * | 2023-06-27 | 2025-01-02 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| CN118290586B (zh) * | 2024-04-02 | 2025-11-04 | 郑州伊美诺生物技术有限公司 | 一种分泌kod dna聚合酶单克隆抗体的杂交瘤细胞、单克隆抗体及其应用 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| SG11201700258VA (en) | 2014-07-16 | 2017-02-27 | Genentech Inc | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| AU2015305754B2 (en) * | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| SG11201704741PA (en) | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN108136015A (zh) * | 2015-08-20 | 2018-06-08 | 艾伯维施特姆森特克斯有限责任公司 | 抗dll3抗体药物缀合物以及使用方法 |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| PL3356413T3 (pl) * | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania |
| CN109071656B (zh) * | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
-
2019
- 2019-01-15 KR KR1020207020419A patent/KR20200109313A/ko not_active Withdrawn
- 2019-01-15 AU AU2019207296A patent/AU2019207296A1/en not_active Abandoned
- 2019-01-15 WO PCT/CN2019/071711 patent/WO2019137548A1/en not_active Ceased
- 2019-01-15 US US15/733,364 patent/US11708410B2/en active Active
- 2019-01-15 TW TW108101551A patent/TW201932489A/zh unknown
- 2019-01-15 SG SG11202005595YA patent/SG11202005595YA/en unknown
- 2019-01-15 EP EP19738954.7A patent/EP3740508A4/en not_active Withdrawn
- 2019-01-15 CA CA3088332A patent/CA3088332A1/en active Pending
- 2019-01-15 JP JP2020539000A patent/JP7316284B2/ja active Active
- 2019-01-15 CN CN201980008439.XA patent/CN111601826B/zh active Active
-
2020
- 2020-06-29 IL IL275737A patent/IL275737A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510710A5 (https=) | ||
| JPWO2019137548A5 (https=) | ||
| JP7813721B2 (ja) | Ｎｅｃｔｉｎ－４に対する抗体及びその用途 | |
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| CN115052895B (zh) | 抗SIRPα抗体及其用途 | |
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2021524242A (ja) | 抗−ｒｏｒ１抗体およびその用途 | |
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2015519375A5 (https=) | ||
| WO2018053709A1 (en) | The novel monoclonal antibodies to programmed death 1 (pd-1) | |
| JP2019527553A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| CN111635458A (zh) | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 | |
| JP2024001073A5 (https=) | ||
| CN113993901A (zh) | 四价双特异性抗体、其制备方法和用途 | |
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| WO2021084104A1 (en) | Tetravalent antibody molecules | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| CN120035609A (zh) | Pd-1激动剂抗体 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| WO2020039049A1 (en) | Anti-sirpg compounds | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |